2. UroToday Home
  3. Video Lectures
  4. Clinical Case-Based Learning

Clinical Case-Based Learning VL

Tumor Board Reviewing the Use of PSMA PET in Patient with Gleason 4+5=9, GG 5 Disease, Bone Scan Demonstrated Mild Uptake Prostate Cancer - Session 2 Case 1 - H Jacene, A Kibel, P Nguyen, & A Morgans

Tumor Board Reviewing the Use of PSMA PET in Patient with Gleason 4+5=9, GG 5 Disease, Bone Scan Demonstrated Mild Uptake Prostate Cancer - Session 2 Case 1 - H Jacene, A Kibel, P Nguyen, & A Morgans

Details
In this Clinical Case-Based Learning Educational Program, a Virtual Tumor Board in Prostate Cancer, a case of a 72-year-old male with no past medical history is presented. He has been followed for some time at this point. His PSA in December 2021 was 8.44. His repeat PSA in Feb 2022 was 7.61 and his DRE was notable for having a left-sided firm nodule. His prostate biopsy in March of 2022, was nota...
Tumor Board Reviewing the Use of PSMA PET in the Care of Patient Who Underwent Fluciclovine for Prostate Cancer - Session 1 Case 6

Tumor Board Reviewing the Use of PSMA PET in the Care of Patient Who Underwent Fluciclovine for Prostate Cancer - Session 1 Case 6

Details
In this Clinical Case-Based Learning Educational Program, a Virtual Tumor Board in Prostate Cancer, a case of a 64 year old man with a history of kidney stones presented, evaluated, and his treatment plan addressed. Independent Medical Education Initiative Supported by Progenics Pharmaceuticals, Inc. a subsidiary of Lantheus Holdings, Inc. Biographies: Heather Jacene, MD, Clinical Director of Nucl...
Tumor Board Reviewing the Use of PSMA PET in the Care of Patient with Gleason 4+5=9, GG 5 with Seminal Vesicle Invasion Prostate Cancer - Session 1 Case 5 - H Jacene, A Kibel, P Nguyen, & A Morgans

Tumor Board Reviewing the Use of PSMA PET in the Care of Patient with Gleason 4+5=9, GG 5 with Seminal Vesicle Invasion Prostate Cancer - Session 1 Case 5 - H Jacene, A Kibel, P Nguyen, & A Morgans

Details
In this Clinical Case-Based Learning Educational Program, a Virtual Tumor Board in Prostate Cancer, a case of a 57 year old man with a history of coronary artery disease and Barrett's esophagus. is presented, evaluated, and his treatment plan addressed. Independent Medical Education Initiative Supported by Progenics Pharmaceuticals, Inc. a subsidiary of Lantheus Holdings, Inc. Biographies: Heather...
Tumor Board Reviewing the Use of PSMA PET in Prostate Cancer Gleason 4+4=8 GG 4, PI-RADS 5 Lesion, Possible Seminal Vesicle Involvement - Session 2 Case 2 - H Jacene, A Kibel, P Nguyen, & A Morgans

Tumor Board Reviewing the Use of PSMA PET in Prostate Cancer Gleason 4+4=8 GG 4, PI-RADS 5 Lesion, Possible Seminal Vesicle Involvement - Session 2 Case 2 - H Jacene, A Kibel, P Nguyen, & A Morgans

Details
In this Clinical Case-Based Learning Educational Program, a Virtual Tumor Board in Prostate Cancer, a case of a 64-year-old man with a history of diabetes came into his local urologist with concerns of irritation on voiding for nine months despite treatment. In March of 2022, he had a PSA of 67.8 and in April he still had an elevated PSA of 56.4. In April, he also had an MRI that showed possible c...
Tumor Board Reviewing the Use of PSMA PET in Prostate Cancer - Gleason 3+3=6 GG 1, PALB2 Mutation - Session 2 Case 3 - H Jacene, A Kibel, P Nguyen, & A Morgans

Tumor Board Reviewing the Use of PSMA PET in Prostate Cancer - Gleason 3+3=6 GG 1, PALB2 Mutation - Session 2 Case 3 - H Jacene, A Kibel, P Nguyen, & A Morgans

Details
In this Clinical Case-Based Learning Educational Program, a Virtual Tumor Board in Prostate Cancer, a case of a 63-year-old man with no significant past medical history is presented. He has a family history of ovarian cancer in his sister. In September 2021, he had a PSA of 6.5. In November, he received a prostate biopsy, where they identified Gleason 3+3=6 Grade Group 1 prostate adenocarcinoma in...
Tumor Board Reviewing the Use of PSMA PET in Prostate Cancer, Gleason 4+4=8 GG 4 - Session 2 Case 6 - H Jacene, A Kibel, P Nguyen, & A Morgans

Tumor Board Reviewing the Use of PSMA PET in Prostate Cancer, Gleason 4+4=8 GG 4 - Session 2 Case 6 - H Jacene, A Kibel, P Nguyen, & A Morgans

Details
In this Clinical Case-Based Learning Educational Program, a Virtual Tumor Board in Prostate Cancer, a case of a 74 year old man with a past medical history of high risk localized prostate cancer is presented and discussed. He had a PSA of 54 in January 2021, an MRI with a PI-RADS five lesion on the right that was biopsied and demonstrated to be a Gleason 4+4 grade group four, prostate adenocarcino...
Tumor Board Reviewing the Use of PSMA PET in Prostate Cancer -Gleason 3+4=7, GG 2 (left) Gleason 3+3=6 GG 1 (right), Notable Lymph Node Enlargement Session 2 Case 5 - H Jacene, A Kibel, P Nguyen, & A Morgans

Tumor Board Reviewing the Use of PSMA PET in Prostate Cancer -Gleason 3+4=7, GG 2 (left) Gleason 3+3=6 GG 1 (right), Notable Lymph Node Enlargement Session 2 Case 5 - H Jacene, A Kibel, P Nguyen, & A...

Details
In this Clinical Case-Based Learning Educational Program, a Virtual Tumor Board in Prostate Cancer, a case of a 65-year-old man with a history of stage IV marginal zone lymphoma with a PSA of 4.53 in December of 2021. He underwent an MRI of the prostate in March of 2022, which was an incomplete study due to claustrophobia, but they were able to identify multiple partially imaged enlarged lymph nod...
Tumor Board Reviewing the Use of PSMA PET in Prostate Cancer - Gleason 4+4=8 GG 4, 12 of 12 Cores, High Risk Localized Disease - Session 2 Case 4 - H Jacene, A Kibel, P Nguyen, & A Morgans

Tumor Board Reviewing the Use of PSMA PET in Prostate Cancer - Gleason 4+4=8 GG 4, 12 of 12 Cores, High Risk Localized Disease - Session 2 Case 4 - H Jacene, A Kibel, P Nguyen, & A Morgans

Details
In this Clinical Case-Based Learning Educational Program, a Virtual Tumor Board in Prostate Cancer, a case of a 62-year-old man with a history of hypertension. In November of 2021, the patient had a PSA test that was notable for being 57.58. In January, the patient came in for a biopsy Gleason 4+4=8, grade group 4. Prostate adenocarcinoma was identified in 12 of 12 cores. In February of 2022, the...
Tumor Board Reviewing the Use of PSMA PET in the Care of Patient with Gleason 3+4=7 GG 2, 3 Cores on Right, 6 Negative Cores Prostate Adenocarcinoma - Session 1 Case 3 - H Jacene, A Kibel, P Nguyen, & A Morgans

Tumor Board Reviewing the Use of PSMA PET in the Care of Patient with Gleason 3+4=7 GG 2, 3 Cores on Right, 6 Negative Cores Prostate Adenocarcinoma - Session 1 Case 3 - H Jacene, A Kibel, P Nguyen, &...

Details
In this Clinical Case-Based Learning Educational Program, a Virtual Tumor Board in Prostate Cancer, a case of a 69-year-old man with a history of Crohn's disease that's under control, arthritis, chronic HCV, hypertension, and non-muscle-invasive bladder cancer is presented, evaluated, and his treatment plan addressed. Independent Medical Education Initiative Supported by Progenics Pharmaceuticals,...
Tumor Board Reviewing the Use of PSMA PET in Patient with Gleason 3+4=7 with MLH1 Pathogenic Mutation Prostate Adenocarcinoma - Session 1 Case 2 - H Jacene, A Kibel, P Nguyen, & A Morgans

Tumor Board Reviewing the Use of PSMA PET in Patient with Gleason 3+4=7 with MLH1 Pathogenic Mutation Prostate Adenocarcinoma - Session 1 Case 2 - H Jacene, A Kibel, P Nguyen, & A Morgans

Details
In this Clinical Case-Based Learning Educational Program, a Virtual Tumor Board in Prostate Cancer, a case of a 66 year old man with a history of hypertension and hypercholesterolemia is presented, evaluated, and his treatment plan addressed. Independent Medical Education Initiative Supported by Progenics Pharmaceuticals, Inc. a subsidiary of Lantheus Holdings, Inc. Biographies: Heather Jacene, MD...